Drug-induced cutaneous vasculitis developing during Etanercept treatment for rheumatoid arthritis
Biological disease-modifying anti-rheumatic drugs (bDMARDs) are widely used for the treatment of chronic inflammatory rheumatic diseases. Since the introduction of tumor necrosis factor alpha (TNF-) inhibitors, the treatment of rheumatoid arthritis has been revolutionized. The approach of targeting...
Enregistré dans:
Auteurs principaux: | Maria N. Chamurlieva, Yulia L. Korsakova, Stefka G. Radenska-Lopovok, Tatiana V. Korotaeva |
---|---|
Format: | article |
Langue: | RU |
Publié: |
State Scientific Center of Dermatovenereology and Cosmetology
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/91175d6222fa48c88b9edfe7b48b771d |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Clinical Improvements as Predictors of Improvements in Patient-Reported Outcomes: Post Hoc Analysis of a Randomized, Open-Label Study of Etanercept in Latin American Patients with Rheumatoid Arthritis
par: Guerra Bautista G, et autres
Publié: (2019) -
Revisiting the question of cutaneous vasculitis classification
par: Alexey V. Samtsov, et autres
Publié: (2021) -
Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
par: Mysler E, et autres
Publié: (2021) -
Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report
par: Yeqing Xiao, et autres
Publié: (2021) -
Management of rheumatoid arthritis during pregnancy: challenges and solutions
par: Krause ML, et autres
Publié: (2016)